Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

carboplatin

CARBOPLATIN ACCORD

carboplatin (CARBOPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved NMPA: clinical trials
US status approved
Patents linked 20
Pipeline programs 224
News articles 0
Drug details — carboplatin
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
224
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

carboplatin (CARBOPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN carboplatin
Brand CARBOPLATIN ACCORD
Mechanism DNA inhibitor
Target DNA
Route INJECTION
Formulation INJECTABLE
Originator Accord Healthcare Pty.

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
FDA approved —
TGA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. 1407-GUCG Phase 3 · Ningbo Cancer Hospital · Progressive or recurrent germ cell tumor (measurable or non-
  2. 1438-0011 Phase 3 · Boehringer Ingelheim · advanced or metastatic extrapulmonary neuroendocrine carcino
  3. 1438-0012 Phase 3 · Boehringer Ingelheim · small cell lung cancer
  4. 1479-0008 Phase 3 · Boehringer Ingelheim · non-squamous non-small cell lung cancer
  5. 2019/2894 Phase 3 · George Institute for · Patients with High Risk Neuroblastoma
  6. 20200041 Phase 3 · Amgen · Extensive stage small cell lung cancer (ES-SCLC)
  7. 20240178 Phase 3 · Amgen · Extensive stage small cell lung cancer (ES-SCLC).
  8. 22615 Phase 3 · Bayer · Advanced non-small cell lung cancer with HER2 (ERBB2) mutati

Related & competitor drugs

Browse all drugs
  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents Accord Healthcare Pty. patent hub

  1. WO 2026082899

    ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026068864

    DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE

    Expires Wed Mar 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026062193

    COMPOSITIONS ET PROCÉDÉS

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026058153

    UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026057626

    PEPTIDOGLYCANE HYDROLASES AYANT DE MULTIPLES DOMAINES ENZYMATIQUEMENT ACTIFS

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026057625

    PEPTIDOGLYCANE HYDROLASES AYANT UN DOMAINE CHAP AVEC SITE ACTIF MODIFIÉ

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026047601

    RÉCEPTEURS DE LYMPHOCYTES T (TCR)

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026033380

    PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES

    Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026027695

    COMPOSITIONS ET PROCÉDÉS

    Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026021698

    PARTICULE D'ACIDE NUCLÉIQUE

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026013643

    PROCÉDÉS ET COMPOSITIONS POUR CONCEVOIR DES CHAÎNES D'ÉPITOPES AVEC DES LIEURS

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2026015857

    COMPOSITION DE VACCIN DESTINÉE À DÉCLENCHER UNE RÉPONSE DES LYMPHOCYTES T CD8+ SPÉCIFIQUE DE L'EBV

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2025261607

    PARTICULES, COMPOSITIONS ET PROCÉDÉS

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2025264662

    COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UN MÉLANOME

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11987590

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11793912

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11512128

    VEGF/DLL4 binding agents and uses thereof

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11434204

    Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11234967

    Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is carboplatin?

carboplatin (CARBOPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for carboplatin?

CARBOPLATIN ACCORD is a marketed brand name for carboplatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of carboplatin?

carboplatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.